Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma

Olaparib for the treatment of BRCA-mutated advanced ovarian cancer

(2016) M. Munroe et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance

(2016) A. Krumm et al.   CANCER RESEARCH

PARP inhibitors and stratified treatment of prostate cancer

(2016) Anita Lavery et al.   Expert Review of Anticancer Therapy

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment

(2016) Anselmo Papa et al.   Journal of Translational Medicine

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model

(2016) Benjamin Lemasson et al.   NEOPLASIA

Advances in PARP inhibitors for the treatment of breast cancer

(2015) Omer Dizdar et al.   EXPERT OPINION ON PHARMACOTHERAPY

PARP inhibitors in BRCA mutation-associated ovarian cancer

(2015) Andrew Clamp et al.   LANCET ONCOLOGY

Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism

(2015) H. Shen et al.   MOLECULAR CANCER THERAPEUTICS

TheMGMTpromoter SNP rs16906252 is a risk factor forMGMTmethylation in glioblastoma and is predictive of response to temozolomide

(2015) Robert W. Rapkins et al.   NEURO-ONCOLOGY

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients

(2015) K Obermeier et al.   ONCOGENE

PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma

(2015) Jara Majuelos-Melguizo et al.   Oncotarget

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide

(2014) Lucio Tentori et al.   BMC CANCER

Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

(2014) S. K. Gupta et al.   CLINICAL CANCER RESEARCH

ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

(2014) F. Lin et al.   CLINICAL CANCER RESEARCH

Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro

(2014) Romana Koppensteiner et al.   PLoS One

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer

(2014) Taofeek K. Owonikoko et al.   Cancer Medicine

Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells

(2013) Lisa A. McPherson et al.   CANCER LETTERS

Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells

(2013) M Venere et al.   CELL DEATH AND DIFFERENTIATION

ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition

(2013) Maria Gilardini Montani et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma

(2013) Lara Barazzuol et al.   Radiation Oncology

In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016

(2009) A. L. Russo et al.   CLINICAL CANCER RESEARCH

Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90

(2009) F. A. Dungey et al.   MOLECULAR CANCER THERAPEUTICS

Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential

(2008) Fiona A. Dungey et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS